In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The stock defied the bear market -- and even gained more than 6%.

The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.

However, there's one big problem on the horizon for AbbVie: Humira is set to face competition, as of next year. AbbVie hasn't yet forecast future sales for Humira, but it's clear declines are ahead. Considering this, where will AbbVie be in about three years? Let's find out.

Continue reading

Source Fool.com